Twist Bioscience Corporation (TWST)

27.69 -0.67 (-2.36%) As of 02:06PM EDT. Market open.

Twist Bioscience Corporation

681 Gateway Boulevard
South San Francisco, CA 94080
United States
800 719 0671
https://www.twistbioscience.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 919

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Emily Marine Leproust Ph.D.	Co-Founder, Chairman & CEO	1.37M	153.71k	1973
Dr. Patrick John Finn Ph.D.	President & COO	943.94k	N/A	1972
Ms. Paula Green	Senior Vice President of Human Resources	618.48k	N/A	1968
Dr. William Charles Banyai Ph.D.	Senior VP of Advanced Development, GM of Data Storage & Director	711.34k	N/A	1955
Mr. Adam Laponis	Chief Financial Officer	N/A	N/A	1977
Mr. Robert F. Werner	VP & Chief Accounting Officer	N/A	N/A	1973
Mr. Siyuan Chen	Chief Technology Officer	N/A	N/A	N/A
Dr. Aaron K. Sato Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Chet Gandhi	Chief Information Officer	N/A	N/A	N/A
Mr. Dennis Cho	Senior VP, Chief Legal Officer & Corporate Secretary	537.93k	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Twist Bioscience Corporation’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.